We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background Combined CTLA-4 and PD-1 blockade induces high rates of immune-related adverse events (irAEs). The safety of resuming anti-PD-1 in patients who discontinue combination therapy due to irAEs is not known. Patients and Methods We assessed patients who experienced clinically significant irAEs from combined CTLA-4 and PD-1 blockade leading to(More)
  • 1